Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
about
HIV protease inhibitors: a review of molecular selectivity and toxicityRaltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infectionEvidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialAgeing and inflammation in patients with HIV infection.HIV-1 drug resistance and resistance testing.Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.The epidemiological impact of HIV antiretroviral therapy on malaria in children.Bibliometric Assessment of European and Sub-Saharan African Research Output on Poverty-Related and Neglected Infectious Diseases from 2003 to 2011.Outcome of patients on second line antiretroviral therapy under programmatic condition in IndiaEfficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in AfricaEfficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN TrialA prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals.HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.A Case Series of Acquired Drug Resistance-Associated Mutations in Human Immunodeficiency Virus-Infected Children: An Emerging Public Health Concern in Rural Africa.Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, MalawiResponse to Therapy in Antiretroviral Therapy-Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor-Associated Transmitted Drug ResistanceRaltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority studyLong-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.Virological efficacy of PI monotherapy for HIV-1 in clinical practice.Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern.Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in EuropeUse of Integrase Inhibitors in HIV-Infected Children and Adolescents.Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe-Africa Research Network for the Evaluation of Second-line Therapy trial.The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.Switching to second-line ART in relation to mortality in a large Tanzanian HIV cohort.Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
P2860
Q28082749-4158B014-030C-4D64-82C5-414CA29AB300Q28543732-91803F50-6A09-42F4-B745-37F296E9365CQ28548288-4CEB80B1-CFC6-429E-95C1-0F2D6682CD8AQ30244296-04CF6FCA-02DC-45DC-9504-4E8C7F52CE19Q30245693-21541BC2-BD34-4BAF-96C4-730E06757E1CQ33589766-4517A0D6-1CB3-4F96-AA24-1D3CCC9CBAE3Q33669836-6F56DF23-E4D0-4376-95AF-F1584D50EEB8Q33712438-3E63B3B0-8A0A-4CD7-8305-D96CA0D4691AQ33764793-1CB29FE0-95D2-4AFD-BD4E-221492CC33D0Q33765196-27469B10-5328-4223-B305-50A8B122E147Q34710691-8D23ECB8-2E73-4E77-97D9-956AB3A7685AQ35347170-4D70A684-DC4F-4088-AB5F-729B9A53BBE0Q35742479-2A36EC34-61DC-4AB9-8AF6-3BA703903FA3Q35842413-BCB3B63A-5387-4C78-99D5-F2B3B251A78EQ35853812-5FDD4802-A89B-4DA6-920A-459B24B03006Q36013412-D00A32A0-937A-4BF5-97F5-9D67226CD322Q36293999-393D3A86-DCF1-4AC9-8CCF-77A19F568C77Q36377132-404E5DDF-507E-434F-86B2-5FA4974D4986Q36426953-1F4859FE-DBF0-44EE-9A21-6D9DF59D1C46Q36488965-18446256-A253-42A9-89AE-3A0AE40D0B19Q36541070-EDF8E32B-A5E4-42D5-830A-C1673D3C6A5AQ36613143-C462D3C9-89E7-40AD-9FBC-24A736F68F88Q36893580-4115CC6B-1EAE-44C9-AF6C-27DE9329B598Q36900951-9770B5DB-8FDD-4C0D-AE72-E3C6CCB14CFBQ37021431-75FF182A-1A17-445C-83B3-823F22C4F89DQ37157278-707C0353-5004-4C85-BAA8-B13DFFDF27F8Q37364894-1C326667-68A1-4642-A1AE-23A456EB6FE8Q37454209-E168DE94-0E97-4628-A877-0718D5234DC3Q37461250-58ECE699-F69B-437C-A916-F88E2EE6EDE5Q37631931-9A0E68ED-76BE-47B3-93C0-22315C3B1D86Q38560855-83CCA3B9-4A6F-4636-BAD9-08D7525EDBC5Q38620257-282B70E1-5D69-465C-91AE-163864AD7B94Q38621767-B4D549C3-EF98-40E8-905E-A31609FFC6E6Q38673571-C81DE719-34E5-4155-85DE-86F62EC37B27Q38737182-88883DF7-ED43-487A-B7F5-F752AE8A45EEQ38791126-2C78DE22-FDFE-402D-92E8-10CA3A07CCCEQ38848107-917F9215-5DD5-4B4F-8C18-04EA8640DE7EQ38849598-166DC611-26E3-491A-B0FF-653367736A0AQ38853866-45BDEEDB-995B-448E-BB1C-300E02671631Q38854117-73636C9D-599B-4ABD-A302-6D77B649B748
P2860
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
@en
type
label
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
@en
prefLabel
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
@en
P2093
P356
P1476
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
@en
P2093
A Sarah Walker
Abbas Lugemwa
Abraham Siika
Aggrey Mweemba
Andrew Kambugu
Andrew Reid
Anne Hoppe
Cissy Kityo
Dickens Atwongyeire
Dinah Tumukunde
P304
P356
10.1056/NEJMOA1311274
P407
P577
2014-07-01T00:00:00Z